Merck’s new Alzheimer’s drug shows positive results

Merck’s new new Alzheimer’s drug (currently being evaluated in two Phase 3 clinical trials) has shown positive results in targeting the most visible sign of the disease in the patient’s brain. These results have had a very positive impact on the patient community suffering from Alzheimer’s as this could possibly be the first new treatment for the disease in more than a decade.

“We believe this research has the potential to contribute important evidence regarding the amyloid hypothesis, a leading scientific theory for what causes Alzheimer’s disease, and we look forward to seeing the data from our ongoing Phase 3 clinical trials,” Dr. Michael Egan, vice president of clinical development neurosciences at Merck Research Laboratories, said in a statement.

For the full story please visit :